# Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

> **NCT01967095** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- EGFR-Mutant Lung Cancer

## Interventions

- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT01967095
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-15
- **Primary completion:** 2018-11-08
- **Final completion:** 2018-11-08
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967095, "Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01967095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*